CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...

Anktiva, also known as nogapendekin alfa inbakicept, is a new cancer therapy that boosts the immune system to target cancer ...

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course.

About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...